Why the study?
The comparative efficacy of statins versus ɑ blockers for treating benign prostatic hyperplasia in patients with metabolic syndrome was unclear.
Does atorvastatin alone or combined with tamsulosin improve IPSS, QoL, and maximum urinary flow rate in patients with benign prostatic hyperplasia and metabolic syndrome compared to tamsulosin alone?
RCT (n=300)
Randomly distributed
Does atorvastatin alone or combined with tamsulosin improve IPSS, QoL, and maximum urinary flow rate in patients with benign prostatic hyperplasia and metabolic syndrome compared to tamsulosin alone?
Statins, alone or in combination with alpha-blockers, may improve clinical and metabolic parameters in patients with BPH and metabolic syndrome.
Answers are grounded in this paper and cite their sources.
Supports statin addition for BPH with metabolic syndrome; extends pleiotropic benefits to urologic outcomes in RCT data.
Objective To compare the efficacy of statins and ɑ blockers drug therapies for benign prostatic hyperplasia (BPH) in patients with metabolic syndrome (MetS).Materials and method A total of three hundred patients were randomly distributed into three groups of one hundred patients each. Group 1 received only ɑ-adrenoceptor antagonist (ɑ-blocker, AB) (Tamsulosin), group 2 received only statin (atorvastatin), and group 3 received AB plus statin (Tamsulosin + Atorvastatin). The efficacy measurement was assessed by analyzing the changes from baseline in the total International Prostate Symptom Score (IPSS), disease-specific QoL question score and maximum urinary flow rate at the end of 6 months in each group and between the three groups.Results Pre-treatment and post-treatment value of triglycerides (TG), high-density lipoprotein (HDL), and prostate volüme (PV) were not significantly different in AB group, while TG and PV were significantly lower in patients taking statin and combined therapy. The significant decrease was demonstrated in maximum urinary flow rate (Qmax) in three groups. However, the most significant decrease was observed in the combination therapy group. IPSS, postvoid residual urine volüme (PVR), and Quality of Life score (QoL) significantly changed in three groups.Conclusion We recommend of the use of statins in those men with BPH accompanied by MetS in which AB is ineffective alone.
No takes yet. Share an insight, caveat, or question.
Çakır et al. (2018) conducted an RCT in Benign prostatic hyperplasia with metabolic syndrome (n=300). Atorvastatin (with or without Tamsulosin) vs. Tamsulosin alone was evaluated on Changes from baseline in total IPSS, disease-specific QoL score, and maximum urinary flow rate.
Synapse has enriched 10 related papers. Consider them for comparative context: